Carcinoma, Transitional Cell - 25 Studies Found
| Completed |
: The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma : Carcinoma, Transitional Cell : 2010-08-25 |
| Recruiting |
: A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010] : Carcinoma, Transitional Cell : 2015-05-19 : Drug: Atezolizumab Atezolizumab will be administered at a dose of 1200 milligrams (mg). |
| Not yet recruiting |
: Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract : Carcinoma, Transitional Cell : 2017-02-09 :
|
| Withdrawn |
: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma : Urothelial Carcinoma : 2010-02-18 :
|
| Withdrawn |
: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma : Urothelial Carcinoma : 2014-10-28 : Drug: BIBF1120 BIBF1120 200 mg two times per day orally |
| Completed |
: 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen :
: 2005-09-12 : Drug: Gemcitabine |
| Withdrawn |
: Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma : Urothelial Carcinoma : 2013-07-16 :
|
| Withdrawn |
: Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma : Carcinoma, Transitional Cell : 2005-09-12 : Drug: Lycopene |
| Recruiting |
: A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma : Urothelial Carcinoma : 2016-08-16 : Drug: INCB054828 INCB054828 once daily on a 2-weeks-on-therapy and 1-week-off-therapy schedule |
| Completed |
: Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma : Urothelial Carcinoma : 2012-05-23 : Drug: Valrubicin Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days |